How does sitagliptin work? DPP-4 inhibitors and GLP-1 mimetics

DPP-4 Inhibitors vs. GLP-1 Agonists: Why the Distinction Matters

Zero To Finals is a medical education channel aimed at junior doctors and medical students, and this video on sitagliptin and the DPP-4 inhibitor class is a clear example of why their content resonates beyond that audience. With over 220,000 views, plenty of patients and curious non-clinicians have found their way to this one, and it is easy to see why. The video tackles a question that most GLP-1 content skips entirely: how do DPP-4 inhibitors like sitagliptin relate to GLP-1 agonists like semaglutide, and why would a doctor choose one over the other?

The short answer is that both drug classes work through the incretin system, but they take different approaches. DPP-4 inhibitors block the enzyme that breaks down your body's own natural GLP-1, so your existing hormone sticks around a bit longer. GLP-1 agonists skip that step entirely and flood your system with a synthetic version of the hormone at much higher levels than your body would ever produce on its own. This difference in approach explains the different potency levels between the two classes.

Understanding this distinction is genuinely useful for patients, more than med students. If your doctor prescribes sitagliptin (Januvia) instead of semaglutide (Ozempic), it helps to know that you are getting a milder intervention that works with your existing hormone levels rather than replacing them. The trade-off is less dramatic blood sugar reduction and minimal weight loss with DPP-4 inhibitors, compared to the more powerful effects of GLP-1 agonists.

How the Incretin System Works (The Version You Actually Need)

The video walks through the incretin system with diagrams that make the biology click. Here is the flow: you eat food, your gut releases GLP-1 and GIP, these hormones travel to your pancreas and stimulate insulin release while suppressing glucagon. Under normal conditions, the enzyme DPP-4 breaks down GLP-1 within a few minutes, so the effect is short-lived and matched to meals.

DPP-4 inhibitors like sitagliptin put a brake on that enzyme. With DPP-4 partially blocked, your natural GLP-1 hangs around longer, giving your pancreas a slightly extended signal to produce insulin after meals. It is a gentle nudge, not a shove. That is why DPP-4 inhibitors tend to be well tolerated with fewer GI side effects compared to GLP-1 agonists, but also why they produce more modest results in terms of both blood sugar reduction and weight change.

GLP-1 agonists, on the other hand, bypass the natural system entirely. The synthetic hormone in drugs like semaglutide or liraglutide is resistant to DPP-4 breakdown and present at concentrations far above what your gut would ever release. That is why they produce stronger appetite suppression, more significant weight loss, and greater blood sugar reduction. But it is also why the GI side effects (nausea, vomiting, constipation) tend to be more common and more intense, at least early on.

What the Video Gets Right

The head-to-head comparison between DPP-4 inhibitors and GLP-1 agonists is the real value here. Most patient-facing content treats GLP-1 agonists in isolation, as if they are the only option in this space. Zero To Finals correctly shows that these drugs exist on a spectrum of incretin-based therapies, and the right choice depends on the individual patient's needs, tolerance, and treatment goals. The explanation of why DPP-4 inhibitors do not cause significant hypoglycemia (because they only enhance insulin secretion in response to actual food intake, not at baseline) is clearly presented and clinically accurate.

The visual of how DPP-4 normally clips GLP-1 and how the inhibitor blocks that process is one of those simple diagrams that makes the concept stick immediately. The video also correctly notes that DPP-4 inhibitors are weight-neutral, meaning they neither cause weight gain nor promote weight loss in most patients. This is a key distinction from both GLP-1 agonists (which promote weight loss) and some older diabetes drugs like insulin or sulfonylureas (which often cause weight gain).

What It Misses

This video is firmly aimed at understanding the pharmacology, so it does not cover practical patient concerns like cost differences, injection versus oral administration preferences, or how to manage the transition if a doctor decides to switch you from one class to the other. It also does not touch on the newer dual agonists like tirzepatide (Mounjaro/Zepbound), which combine GLP-1 and GIP activity and represent the next step beyond either of these classes. The side effect discussion is brief, and there is no content about the real-world experience of taking these medications long-term.

Questions to Bring to Your Doctor

This video arms you with a question most patients never think to ask: why this specific drug class for my situation? Here is how to sharpen that conversation:

Ask your doctor directly whether a DPP-4 inhibitor or a GLP-1 agonist is more appropriate for your goals. If weight loss is a priority alongside blood sugar control, GLP-1 agonists are typically the stronger choice. If you are primarily managing blood sugar and want minimal side effects, a DPP-4 inhibitor might be the right starting point.

Ask about the possibility of combining or sequencing these treatments. Some patients start with a DPP-4 inhibitor and move to a GLP-1 agonist if they need more aggressive treatment later. However, the two classes should not be used together since they work on the same pathway.

Ask about oral versus injectable options. Sitagliptin is a daily pill, while most GLP-1 agonists are injections (though oral semaglutide, Rybelsus, is an exception). If needle aversion is a factor, knowing your options matters.

Ask about how long you should expect to be on the medication. DPP-4 inhibitors are typically long-term prescriptions for diabetes management, while GLP-1 agonists for weight loss raise the question of whether and when to discontinue.

Who Should Watch This

This video is best for anyone who wants to understand the broader family of incretin-based drugs, more than the GLP-1 agonists that dominate headlines. If your doctor has mentioned sitagliptin, saxagliptin, or any DPP-4 inhibitor, this video will give you the background to understand why. If you are already on a GLP-1 agonist and want to understand how it compares to other options in the same therapeutic space, this fills in important context. Medical students and healthcare professionals will find it a clean, efficient refresher. Just be aware that it is purely science-focused, so pair it with patient-experience content for the full picture of what taking these drugs actually looks like day to day.

One underappreciated aspect of this video is how it helps patients understand the treatment ladder for type 2 diabetes. Many patients are started on metformin, then progress to a DPP-4 inhibitor if metformin alone is not sufficient, and may eventually move to a GLP-1 agonist if more aggressive treatment is needed. Understanding where each drug class sits on that ladder, and why, helps you see your own treatment trajectory as a logical progression rather than a series of random medication changes that your doctor is making without explanation.

The video also provides useful context for understanding why combination therapies exist and how they work. Some patients take a DPP-4 inhibitor alongside metformin in a combination pill, while others are prescribed a GLP-1 agonist as a standalone or in combination with other diabetes medications. The incretin framework that Zero To Finals presents helps you see how all these pieces fit together in a treatment strategy, rather than viewing each medication as an isolated intervention that exists in a vacuum.

For anyone who has been told they have pre-diabetes or early-stage type 2 diabetes, this video provides valuable context for understanding what treatments you might encounter as your condition progresses or as treatment guidelines evolve. The more you understand about the available tools, the more productive your conversations with your healthcare team will be, and the better positioned you will be to advocate for the treatment approach that best fits your specific needs and circumstances.

Zero To Finals has built a strong reputation for clinical accuracy, and this video maintains that standard. While the target audience is medical trainees, the clear explanations and logical structure make it accessible to any motivated learner willing to engage with the material at a slightly higher level than typical patient-facing content. That extra depth is exactly what some patients need to feel truly informed about their treatment options.

The cost dimension of DPP-4 inhibitors versus GLP-1 agonists is worth understanding even though the video does not cover it. DPP-4 inhibitors like sitagliptin are available as generics in many markets and are typically less expensive than branded GLP-1 agonists. For patients whose primary need is blood sugar management rather than significant weight loss, a DPP-4 inhibitor may provide adequate control at a fraction of the cost. This is a legitimate medical decision, not a compromise, and the pharmacological understanding this video provides helps patients see why their doctor might choose one class over the other for reasons beyond just efficacy rankings.

The video also creates a useful foundation for understanding why combining a DPP-4 inhibitor with a GLP-1 agonist is not recommended. Since both work through the incretin system, combining them produces diminishing returns while potentially increasing side effect risk. However, both can be safely combined with metformin, insulin, or SGLT2 inhibitors, which work through entirely different mechanisms. This understanding of complementary versus overlapping drug mechanisms helps patients make sense of their medication lists and understand why their doctor adds some drugs together while avoiding other combinations.

Head-to-Head Trial Data: DPP-4 Inhibitors vs. GLP-1 Agonists

The clinical data comparing these two drug classes is unambiguous in terms of efficacy. The SUSTAIN-7 trial, published in The Lancet Diabetes and Endocrinology in 2018, compared semaglutide against dulaglutide (both GLP-1 agonists), showing HbA1c reductions of 1.5-1.8 percentage points. By contrast, sitagliptin (the original DPP-4 inhibitor, brand name Januvia) typically produces HbA1c reductions of 0.5-0.7 percentage points in clinical trials. The PIONEER-3 trial directly compared oral semaglutide to sitagliptin 100mg and found that semaglutide at both the 7mg and 14mg doses produced significantly greater HbA1c reductions and weight loss. At 26 weeks, oral semaglutide 14mg reduced HbA1c by 1.3 percentage points versus 0.8 for sitagliptin. Weight loss was 3.1 kg with oral semaglutide 14mg compared to 0.6 kg with sitagliptin. The TECOS trial, published in the New England Journal of Medicine in 2015, established that sitagliptin had a neutral effect on cardiovascular outcomes, meaning it neither increased nor decreased heart disease risk. GLP-1 agonists, by comparison, have demonstrated active cardiovascular protection in the SUSTAIN-6, LEADER, and SELECT trials.